Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

PLEKHA4 Promotes Wnt/β-Catenin Signaling-Mediated G1-S Transition and Proliferation in Melanoma.

Cancer research - 15 Apr 2021

Shami Shah Adnan, Cao Xiaofu, White Andrew C, Baskin Jeremy M

Abstract excerpt

Despite recent promising advances in targeted therapies and immunotherapies, patients with melanoma incur substantial mortality. In particular, inhibitors targeting BRAF-mutant melanoma can lead to resistance, and no targeted therapies exist for NRAS-mutant melanoma, motivating the search for additional therapeutic targets and vulnerable pathways. Here we identify a regulator of Wnt/β-catenin signaling, PLEKHA4,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carbamates
Share to Dishevelled Proteins
Share to G1 Phase

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Heterografts

Share to Neoplasm Transplantation

Share to S Phase

Share to Tumor Stem Cell Assay

Share to Wnt Signaling Pathway

Source

Open in PubMed Open full text

Identifiers

PMID: 33574086
DOI: 10.1158/0008-5472.CAN-20-2584
PMCID: PMC8137570

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

PLEKHA4 Promotes Wnt/β-Catenin Signaling-Mediated G1-S Transition and Proliferation in Melanoma.PMID 33574086Read ↗

PLEKHA4 is a prognostic biomarker and correlated with immune infiltrates in gliomaSemantic proximity Read ↗

Diacylglycerol Kinase Eta as a Novel Target in NRAS Mutant Melanoma.Semantic proximity Read ↗

PLEKHH2 binds β-arrestin1 through its FERM domain, activates FAK/PI3K/AKT phosphorylation, and promotes the malignant phenotype of non-small cell lung cancer.Semantic proximity Read ↗

The Cell-Cycle Regulator CDK4: An Emerging Therapeutic Target in MelanomaSemantic proximity Read ↗

Nischarin expression may have differing roles in male and female melanoma patientsSemantic proximity Read ↗

The interplay of CDK4 and CDK6 in melanomaSemantic proximity Read ↗

INPP4B is upregulated and functions as an oncogenic driver through SGK3 in a subset of melanomasSemantic proximity Read ↗

The epigenetic modifier EZH2 controls melanoma growth and metastasis through silencing of distinct tumour suppressors.Semantic proximity Read ↗

PSMD14 drives melanoma cell survival and MAPK inhibitor resistance through histone H2A deubiquitinationSemantic proximity Read ↗

KLF4 is regulated by RAS/RAF/MEK/ERK signaling through E2F1 and promotes melanoma cell growthSemantic proximity Read ↗

ROCK1 is a potential combinatorial drug target for BRAF mutant melanoma.Semantic proximity Read ↗

LIN28B: an orchestrator of oncogenic signaling in neuroblastoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.